FIELD: biotechnology.
SUBSTANCE: described are antibody-drug conjugates (ADC), which bind to the FLT3 protein and variants thereof. FLT3 has a pronounced and restricted expression profile in normal tissues/tissues in adults, and its expression is changed in malignant tumors listed in Table I.
EFFECT: thus, ADC under the invention provide a therapeutic composition for treating a malignant tumor.
18 cl, 10 tbl, 15 ex, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AND DRUG CONJUGATES AS A SPLICING MODULATOR AND METHODS OF THEIR USE | 2019 |
|
RU2799438C2 |
| CONJUGATE OF ANTI-IGF-1R ANTIBODY WITH DRUG AND USE THEREOF FOR TREATING CANCER | 2015 |
|
RU2692563C2 |
| ANTIBODY AND MEDICINAL AGENT CONJUGATE AND USE THEREOF FOR TREATING CANCER | 2015 |
|
RU2685259C2 |
| NOVEL ANTIBODY CONJUGATES AND USES THEREOF | 2014 |
|
RU2684468C2 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC TO CD123 AND THEIR USE | 2018 |
|
RU2789150C2 |
| ANTIBODIES TO B7-H3 AND CONJUGATES OF ANTIBODY AND DRUG | 2017 |
|
RU2764651C2 |
| PEPTIDOMIMETIC COMPOUNDS AND THEIR CONJUGATES OF ANTIBODIES WITH DRUGS | 2014 |
|
RU2689388C1 |
| NEW CONJUGATES BINDING COMPOUND - ACTIVE COMPOUND (ADC) AND USE THEREOF | 2012 |
|
RU2610336C2 |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
